Kala Bio (KALA) Receivables (2019 - 2023)
Kala Bio (KALA) posted Receivables of $119000.0 for Q4 2023, down 87.45% sequentially from $948000.0 in Q1 2023, and down 91.88% YoY from $1.5 million in Q4 2022.
Kala Bio (KALA) Receivables (2019 - 2023) Analysis & Trends
Kala Bio has reported Receivables for 5 years, with the latest figure at $119000.0 in Q4 2023.
- Quarterly Receivables fell 91.88% year-over-year to $119000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $119000.0 (down 91.88% YoY) and the FY2023 annual result came in at $119000.0, down 94.93% from the prior year.
- Receivables slipped to $119000.0 in Q4 2023 per KALA's latest filing, from $948000.0 in the prior quarter.
- Over five years, Receivables peaked at $17.5 million in Q4 2021 and troughed at $119000.0 in Q4 2023.
- A 5-year average of $7.8 million and a median of $7.3 million in 2019 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2022: Receivables surged 177.01% in 2021, then plunged 98.5% in 2022.
- Over 5 years, Receivables stood at $13.1 million in 2019, then fell by 24.77% to $9.9 million in 2020, then jumped by 77.14% to $17.5 million in 2021, then plunged by 91.61% to $1.5 million in 2022, then plunged by 91.88% to $119000.0 in 2023.
- According to Business Quant data, Receivables over the past three periods registered $119000.0, $948000.0, and $1.5 million for Q4 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Kala Bio | 9.97 Mn | 9.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 119,000.00 |
| Mar 31, 2023 | 948,000.00 |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 190,000.00 |
| Jun 30, 2022 | 13.82 Mn |
| Mar 31, 2022 | 13.02 Mn |
| Dec 31, 2021 | 17.46 Mn |
| Sep 30, 2021 | 12.63 Mn |
| Jun 30, 2021 | 11.86 Mn |
| Mar 31, 2021 | 12.21 Mn |
| Dec 31, 2020 | 9.85 Mn |
| Sep 30, 2020 | 7.46 Mn |
| Jun 30, 2020 | 4.28 Mn |
| Mar 31, 2020 | 4.79 Mn |
| Dec 31, 2019 | 13.10 Mn |
| Sep 30, 2019 | 7.17 Mn |
| Jun 30, 2019 | 5.65 Mn |
| Mar 31, 2019 | 4.67 Mn |